MANNKIND CORP Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares
MANNKIND CORP (MNKD) reported Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares of 32.00 thousand shares for the 12-month period ending 2016-12-31, per its 10-K filed 2019-02-26.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares · last filed 2019-02-26
- MANNKIND CORP incremental common shares attributable to dilutive effect of contingently issuable shares for the quarter ending 2016-09-30 was 921.00K shares.
- MANNKIND CORP incremental common shares attributable to dilutive effect of contingently issuable shares for fiscal 2016 was 32.00K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 3 month | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 9 month | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 9 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 12 month |
|---|---|---|---|---|---|
| 2016-12-31 | 32.00K shares 10-K · filed 2019-02-26 | ||||
| 2016-09-30 | 921.00K shares 10-Q · filed 2017-11-07 | 4.61M shares 10-Q · filed 2016-11-09 | 36.00K shares 10-Q · filed 2017-11-07 | 178.00K shares 10-Q · filed 2016-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |